Multibagger Selection: Claude Opus 5.5's picks

RCAT

Red Cat makes the Black Widow small drone, selected as the US Army's program-of-record system. The company has reaffirmed a FY2026 revenue target of $150M-$180M, against $35.7M in 1H 2026 (Q1 $15.5M, Q2 $20.2M). Management is therefore guiding to a step-function 2H ramp, which Q3/Q4 results will confirm or refute. The stock trades at about 3x EV to guided-midpoint revenue after a heavy de-rating, and it holds $325.6M of cash. If the ramp is delivered, the market is likely to reprice the company as a scaled defense hardware supplier. If it misses, the downside is cushioned in part by cash at roughly 39% of market cap. Price: $5.51 intraday on 2026-10-12, the most recent quote found. A live quote for 2026-10-21 could not be retrieved.

LPTH

LightPath is mid-transition from optical components to infrared camera and assembly systems for defense, including counter-UAS and drone programs. It shows the full inflection sequence:

- Revenue: FY2026 (June year end) revenue +93% to $71.7M.

- Gross margin: 27% to 36% for the year, 39.4% in Q4.

- Operating leverage: adjusted EBITDA swung from a $5.1M loss to a $4.2M profit.

- Backlog: $110.9M (+197%), of which $85.6M is requested for delivery within 12 months.

The stock has fallen about 49% from its $18.94 52-week high while the backlog kept growing. Price: $9.72 regular-session close on 2026-10-09, the most recent quote found.

ONDS

Ondas is now a scaled autonomous defense and counter-drone platform.

- Q2 2026 revenue was $83.8M, 13x YoY and +85% on a pro forma organic basis.

- FY2026 guidance was raised to $525M-$550M, Q3 2026 guidance is $140M-$155M, and management targets exiting 2026 at a $1B annualized run rate.

- Pro forma backlog was $757M at Jun 30, 2026, and the company reported more than $165M of new orders after its last update in early October.

- Cash and short-term investments were $1.4B.

Despite this, the stock is down about 35% year to date and trades at roughly 2x EV to the exit run rate. The large share count (about 570.6M) limits per-share upside. Price: $6.25 intraday on 2026-10-20 (10:51 AM ET), the most recent quote found.

AEHR

Aehr's FY2027 guidance (year ending Jun 25, 2027) is $130M-$150M revenue, +160% to +200%, with an 18-22% non-GAAP net margin. Much of it is backed by an effective backlog of about $100.6M, after record Q4 FY2026 bookings of $60.7M.

- The lead hyperscale AI customer has adopted Sonoma burn-in for a second AI processor (follow-on orders of about $6M announced Oct 7, 2026). The customer expects that processor's volumes to exceed the first's in a 2027 ramp.

- The stock has fallen from a $109.48 October high to the low $60s.

- At about $2.1B, it now trades near 15x the FY2027 guide midpoint versus about 35x estimates earlier in the year.

Price: $65.29 intraday on 2026-10-19, the most recent quote found. A 2026-10-20 or 2026-10-21 quote could not be retrieved.

CAPR

Capricor is a binary regulatory situation with substantial cash backing. The FDA action date (PDUFA) for the deramiocel BLA in Duchenne muscular dystrophy cardiomyopathy and upper-limb function is Nov 22, 2026, after the FDA extended review to assess 24-month HOPE-3 data supporting a narrower upper-limb indication. Market cap is $384M against $237.9M of cash (Jun 30, 2026), so the market assigns little value to approval. Approval would likely reprice the stock toward or beyond its $40.37 52-week high. The evidence quality is weak: the FDA briefing document stated that HOPE-3 together with HOPE-2 does not provide substantial evidence of effectiveness, an advisory panel voted negatively, and at least one analyst expects a Complete Response Letter. Confidence is therefore low. Price: $6.61 regular-session close on 2026-10-20.